Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Management of FAWT in the AREN0321 and AREN03B2 studies

Amy Armstrong, MD, University Hospitals Cleveland Medical Center, Cleveland, OH, comments on the AREN0321 and AREN03B2 studies (NCT00335556), which both enrolled patients with focal anaplastic Wilms tumor (FAWT). The former study assessed the tumor histology and stage of patients with a pathology, surgery, and radiology review, and the latter included patients from the first study, who were subsequently treated with chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.